Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

1(16.7%)

N/A

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06940674Phase 3Recruiting

Adjunctive Cannabidiol for Recovery From Opioid Study

Role: collaborator

NCT03209609Not ApplicableCompleted

VEST Venous Graft External Support Pivotal Study

Role: collaborator

NCT04598919Phase 1Active Not Recruiting

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Role: collaborator

NCT01121263Completed

Hybrid Revascularization Observational Study

Role: collaborator

NCT00483197Phase 3Unknown

VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial

Role: collaborator

NCT00490321Phase 3Unknown

VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy

Role: collaborator

NCT00490347Phase 2Completed

VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial

Role: collaborator

All 7 trials loaded